10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# Anti-CD35-AcalephFluor488-labled

Catalog # AP101460

## Product Information

| | |
|---|---|
| **Application** | FC, IF/IC |
| **Primary Accession** | P17927 |
| **Reactivity** | Human |
| **Clonality** | Monoclonal |
| **Calculated MW** | 223663 |

## Additional Information

| | |
|---|---|
| **Gene ID** | 1378 |
| **Other Names** | C3BR; Complement receptor type 1; C3b/C4b receptor; CD antigen CD35 |
| **Target/Specificity** | Recognizes human CD35 |
| **Dilution** | FC~~1:10~50 IF/IC~~N/A |
| **Format** | Mouse IgG1. Liquid in PBS, pH 7.3, 0.2% BSA, and 0.02% sodium azide. |
| **Storage** | Store at -20 °C.Stable for 12 months from date of receipt |

## Protein Information

| | |
|---|---|
| **Name** | CR1 |
| **Synonyms** | C3BR |
| **Function** | Membrane immune adherence receptor that plays a critical role in the capture and clearance of complement-opsonized pathogens by erythrocytes and monocytes/macrophages (PubMed:2963069). Mediates the binding by these cells of particles and immune complexes that have activated complement to eliminate them from the circulation (PubMed:2963069). Also acts in the inhibition of spontaneous complement activation by impairing the formation and function of the alternative and classical pathway C3/C5 convertases, and by serving as a cofactor for the cleavage by factor I of C3b to iC3b, C3c and C3d,g, and of C4b to C4c and C4d (PubMed:2972794, PubMed:8175757). Also plays a role in immune regulation by contributing, upon ligand binding, to the generation of regulatory T cells from activated helper T cells (PubMed:25742728). |
| **Cellular Location** | Membrane; Single- pass type I membrane protein |
| **Tissue Location** | Present on erythrocytes, a subset of T cells, mature B cells, follicular dendritic cells, monocytes and granulocytes |

## Background

AcalephFluor488-labled mouse monoclonal antibody to CD35

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.